Spruce Biosciences, Inc. (SPRB)
60.78
-2.52
(-3.98%)
USD |
NASDAQ |
Aug 28, 16:00
60.60
-0.18
(-0.30%)
Pre-Market: 20:00
Spruce Biosciences Shareholders Equity (Quarterly) : 83.73M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 83.73M |
| March 31, 2026 | 34.65M |
| December 31, 2025 | 42.52M |
| September 30, 2025 | 5.386M |
| June 30, 2025 | 13.18M |
| March 31, 2025 | 15.32M |
| December 31, 2024 | 28.82M |
| September 30, 2024 | 51.64M |
| June 30, 2024 | 59.17M |
| March 31, 2024 | 66.62M |
| December 31, 2023 | 76.51M |
| September 30, 2023 | 85.38M |
| June 30, 2023 | 96.56M |
| March 31, 2023 | 108.00M |
| Date | Value |
|---|---|
| December 31, 2022 | 68.49M |
| September 30, 2022 | 78.48M |
| June 30, 2022 | 89.12M |
| March 31, 2022 | 100.24M |
| December 31, 2021 | 111.37M |
| September 30, 2021 | 119.72M |
| June 30, 2021 | 130.11M |
| March 31, 2021 | 140.72M |
| December 31, 2020 | 149.43M |
| September 30, 2020 | 64.00M |
| June 30, 2020 | 29.35M |
| March 31, 2020 | |
| December 31, 2019 | -2.824M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Biogen, Inc. | 18.85B |
| PTC Therapeutics, Inc. | -165.36M |
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 102.85M |
| Total Liabilities (Quarterly) | 19.12M |
| Debt to Equity Ratio | 0.0916 |
| Current Ratio | 9.227 |
| Net Debt Paydown Yield | -0.72% |